These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

870 related items for PubMed ID: 21767894

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
    Li S, Liu Z, Zhu F, Fan X, Wu X, Zhao H, Jiang L.
    Oncol Res; 2013; 21(3):137-44. PubMed ID: 24512728
    [Abstract] [Full Text] [Related]

  • 24. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.
    Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM, Golub T, Meyerson M, Tenen DG, Shapiro GI, Halmos B.
    Cancer Res; 2006 Dec 01; 66(23):11389-98. PubMed ID: 17145885
    [Abstract] [Full Text] [Related]

  • 25. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
    Uramoto H, Yamada T, Yano S, Kondo N, Hasegawa S, Tanaka F.
    Anticancer Res; 2012 Sep 01; 32(9):3785-90. PubMed ID: 22993320
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
    Li XY, Wu JZ, Cao HX, Ma R, Wu JQ, Zhong YJ, Feng JF.
    Oncol Rep; 2013 May 01; 29(5):1975-82. PubMed ID: 23440266
    [Abstract] [Full Text] [Related]

  • 29. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.
    de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T, Ripoche H, Lazar V, Dessen P, Harper F, Pierron G, Pinna G, Araujo N, Harel-Belan A, Armand JP, Wong TW, Soria JC, Kroemer G.
    Cancer Res; 2007 Jul 01; 67(13):6253-62. PubMed ID: 17616683
    [Abstract] [Full Text] [Related]

  • 30. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
    Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA, Pao W.
    Clin Cancer Res; 2006 Nov 01; 12(21):6494-501. PubMed ID: 17085664
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
    Cha MY, Lee KO, Kim M, Song JY, Lee KH, Park J, Chae YJ, Kim YH, Suh KH, Lee GS, Park SB, Kim MS.
    Int J Cancer; 2012 May 15; 130(10):2445-54. PubMed ID: 21732342
    [Abstract] [Full Text] [Related]

  • 34. Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers.
    Shien K, Ueno T, Tsukuda K, Soh J, Suda K, Kubo T, Furukawa M, Muraoka T, Maki Y, Tanaka N, Yamamoto H, Kiura K, Mitsudomi T, Toyooka S, Miyoshi S.
    Clin Lung Cancer; 2012 Nov 15; 13(6):488-93. PubMed ID: 22503506
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 44.